The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis

Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study

(2017) M. Jin et al.   JOURNAL OF CLINICAL ONCOLOGY

Gastric Cancer, Version 2.2013

(2017) Jaffer A. Ajani et al.   Journal of the National Comprehensive Cancer Network

A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II).

(2015) Michiya Kobayashi et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of S-1vscapecitabine for the treatment of gastric cancer: A meta-analysis

(2015) An-Bing He   WORLD JOURNAL OF GASTROENTEROLOGY

Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A meta-analysis

(2014) Chunxiang Cao et al.   CANCER SCIENCE

Gastric cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

(2014) T. Waddell et al.   EJSO

S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study

(2014) Yiming Lu et al.   JOURNAL OF CHEMOTHERAPY

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

(2014) Lee M. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of the Efficacy and Safety of S-1-Based and Capecitabine-Based Regimens in Gastrointestinal Cancer: A Meta-Analysis

(2014) Xunlei Zhang et al.   PLoS One

S-1-based therapy versus S-1 monotherapy in advanced gastric cancer: a meta-analysis

(2014) Jun-Rong Wu et al.   TUMOR BIOLOGY

S-1-based versus 5-FU-based chemotherapy as first-line treatment in advanced gastric cancer: a meta-analysis of randomized controlled trials

(2014) Dan-Hong Li et al.   TUMOR BIOLOGY

S-1-based combination therapyvsS-1 monotherapy in advanced gastric cancer: A meta-analysis

(2014) Guo-Fang Liu   WORLD JOURNAL OF GASTROENTEROLOGY

S-1-basedvsnon-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis

(2014) Jian Yang   WORLD JOURNAL OF GASTROENTEROLOGY

Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer

(2013) X. Wang et al.   Clinical & Translational Oncology

A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer

(2013) Dingzhi Huang et al.   EUROPEAN JOURNAL OF CANCER

Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)

(2013) Wasaburo Koizumi et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis

(2013) Xiao-Long Chen et al.   PLoS One

Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis

(2013) Wei-Wei Chen et al.   PLoS One

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis

(2013) Ming-ming He et al.   PLoS One

A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer

(2012) Gun Min Kim et al.   EUROPEAN JOURNAL OF CANCER

A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer

(2012) Kazuhiro Nishikawa et al.   Gastric Cancer

Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301)

(2011) Yoshito Komatsu et al.   ANTI-CANCER DRUGS

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

(2011) Hiroyuki Narahara et al.   Gastric Cancer

Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

(2010) Jaffer A. Ajani et al.   JOURNAL OF CLINICAL ONCOLOGY

S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis

(2010) Jiahao Huang et al.   MEDICAL ONCOLOGY

6509 5-FU/l-LV (RPMI) versus S-1 as first-line therapy in patients with advanced gastric cancer: a randomized phase III non-inferiority trial. (ISO-5FU10 Study Group trial)

(2009) A. Sawaki et al.   EJC SUPPLEMENTS

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study

(2009) Narikazu Boku et al.   LANCET ONCOLOGY

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

(2008) M. Dank et al.   ANNALS OF ONCOLOGY

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

(2008) J-L Lee et al.   BRITISH JOURNAL OF CANCER

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

(2008) Wasaburo Koizumi et al.   LANCET ONCOLOGY